
|Articles|August 1, 2003
Higher Dosing 'Difficult to Straddle'
Author(s)Andrew Bowser
Chicago - Escalating doses of an antibody to CTLA-4 in conjunction with a peptide vaccine showed the induction of antigen-specific immune responses and potential evidence of autoimmunity in patients with stage III/IV resected melanoma, according to Jeffrey M. Weber, M.D., Ph.D.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Delgocitinib Advances to Phase 3 Evaluation for Lichen Sclerosus
2
LEVEL UP Study Shows Benefits of Switching From Dupilumab to Upadacitinib in AD
3
Case-Based Perspectives on Biologic Treatment for Hidradenitis Suppurativa
4
Atopia Therapeutics Reports Positive Preclinical Data for ATP-R13 as Disease-Modifying Oral AD Therapy
5



















